Preoperative chemotherapy plus lapatinib or trastuzumab or both in HER2-positive operable breast cancer (CHERLOB trial)

Valentina Guarneri, Antonio Frassoldati, Federico Piacentini, Gordana Jovic, Simona Giovannelli, Cristina Oliva, PierFranco Conte

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)192-194
Number of pages3
JournalClinical Breast Cancer
Issue number2
Publication statusPublished - 2008


  • Epidermal growth factor receptor
  • Immunohistochemistry
  • Pathologic complete response

ASJC Scopus subject areas

  • Cancer Research

Cite this